NCT00034775 – Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres Posted on October 25, 2019 by tsuperadmin -
Open-label Study Exploring a Switching Regimen From Depot Neuroleptics to Risperidone Depot Microspheres Posted on August 23, 2019 by tsuperadmin -
NCT00526877 – Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres Posted on March 18, 2019 by tsuperadmin -
NCT00299702 – A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia Posted on March 18, 2019 by tsuperadmin -
NCT00821600 – Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia Posted on March 18, 2019 by tsuperadmin -
NCT00297388 – A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (RISPERDAL CONSTA) in Adults With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT00236587 – An Open Label, Long Term Trial of Risperidone Long Acting Microspheres in the Treatment of Patients Diagnosed With Schizophrenia Posted on March 18, 2019 by tsuperadmin -
NCT00236457 – Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT01855074 – Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone Posted on March 18, 2019 by tsuperadmin -
NCT00495118 – Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder – an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85 Posted on March 18, 2019 by tsuperadmin -
The YODA Project